<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261326</url>
  </required_header>
  <id_info>
    <org_study_id>Statin-01</org_study_id>
    <secondary_id>KA 04068gs</secondary_id>
    <nct_id>NCT00261326</nct_id>
  </id_info>
  <brief_title>Simvastatin Treatment of Patients With Acute Optic Neuritis</brief_title>
  <official_title>Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alpharma ApS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the simvastatin treatment improve the visual
      function after 3 months of the inclusion to this project and if the simvastatin influences
      the results on cerebral MRI after 3 and 6 months of the inclusion. In addition the
      development of new demyelinating relapses. In the patients with monosymptomatic acut optic
      neuritis to investigate whether the simvastatin reduces the risk to develop multiple
      sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease in the Central
      Nervous System (CNS). Acute optic neuritis is a common symptom of MS and is considered to
      have the same pathogenesis as MS, where autoimmune and inflammatory mechanisms lead to the
      progression of MS.

      Statins reduce the cholesterol in blood and in addition have anti-inflammatory effects. From
      experimental data and results from pilot projects there is evidence that the statins perform
      anti-inflammatory and immune-modulatory effects and one can expect a beneficial outcome in
      the autoimmune inflammatory diseases after the treatment with statins.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The contrast sensibility of the eye after 3 months of the treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual evokes potentials (VEP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developing MS after 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Optic Neuritis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simvastatin tablets 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>calcium tablets 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>80 mg once daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>calcium tablets once daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Optic Neuritis

          -  Abnormal contrast sensitivity score (&gt;80)

          -  Symptom duration maximum 4 weeks

          -  Men and women between 18 and 59 years old

          -  The patient must be physical and mental able to participate i this project with a 6
             months of the duration

          -  The patient must sign the written consent of the participation before the inclusion.

        Exclusion Criteria:

          -  Optic neuritis earlier in the same eye

          -  Pregnancy

          -  Nursing

          -  Fertile women who do not use contraception

          -  Women who contemplate pregnancy in the duration of the study

          -  Steroid treatment the last 4 weeks before the inclusion

          -  Immune-supressor treatment the last 6 months before the inclusion

          -  Active liver disease or continuous increase of liver enzymes (ASAT, ALAT)without known
             reason.

          -  Kidney failure

          -  Myopathy

          -  Hyperthyroidism

          -  Diabetes mellitus

          -  Alcoholism

          -  Fibrates intake

          -  Statin treatment for other disease

          -  Simultaneous participation in other studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jette L Frederiksen, Dr.Med</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>The clinic of the research for optic neuritis and MS, The Dpt. of Neurology at Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2005</study_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSci Jette Frederiksen</name_title>
    <organization>Glostrup Hospital</organization>
  </responsible_party>
  <keyword>Simvastatin</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 22, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 11, 2014</submitted>
    <returned>August 25, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

